Effect of nano-encapsulation using human serum albumin on anti-angiogenesis activity of bevacizumab to target corneal neovascularization: Development, optimization and in vitro assessment

Narayana, Soumya; Ahmed, Mohammed Gulzar; Nasrine, Arfa

doi:10.1016/j.matpr.2022.06.179

Cited by 9 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By comparing the formulations S2-PB7a and S2-PB7b, it can be noted that an increase in the TW80/BVZ ratio from 2.3 to 4.6 caused a significant increase in the EE (from 62 to 85%). This is in line with the findings reported by Narayana et al, who also found higher EE by increasing Tween 80 concentration [48]. Overall, the values of EE in the formulations of the screening 2 (Table 2) were higher than those found in the formulation screening 1 (Table 1), likely due to the bigger particle size (40-100 μm vs 1-5 μm) and the milder homogenization used in the formulation screening 2.…”

Section: Effect Of the Plga/bvz And Tween® 80/bvz Ratios On The Encap...supporting

confidence: 90%

“…The aim of the formulation screening 2 was to study the effect of the PLGA/BVZ ratio and the Tween® 80/BVZ ratio on the EE and release kinetics when the surfactant is dissolved in the primary water phase (w1) (Table 2). In this screening, Tween has been preferred over Pluronic because, according to the literature, it has been previously mixed in aqueous phases for BVZ micro-and nanoencapsulation, with a beneficial effect on the EE and stability [48,49]. Span has been excluded due to its insolubility in water.…”

Section: Effect Of the Plga/bvz And Tween® 80/bvz Ratios On The Encap...mentioning

confidence: 99%

See 1 more Smart Citation

Biofunctionalization of 3D printed collagen with bevacizumab-loaded microparticles targeting pathological angiogenesis

Abbadessa,

Nuñez Bernal,

Buttitta

et al. 2023

Journal of Controlled Release

View full text Add to dashboard Cite

Section: Effect Of the Plga/bvz And Tween® 80/bvz Ratios On The Encap...supporting

confidence: 90%

Section: Effect Of the Plga/bvz And Tween® 80/bvz Ratios On The Encap...mentioning

confidence: 99%

Biofunctionalization of 3D printed collagen with bevacizumab-loaded microparticles targeting pathological angiogenesis

Abbadessa,

Nuñez Bernal,

Buttitta

et al. 2023

Journal of Controlled Release

View full text Add to dashboard Cite

“…al. fabricated human serum albumin encapsulated bevacizumab nanoparticles containing 0.05 g tween 80 with PDI=0.8 [41] . .Tayyab et al.…”

Section: Resultsmentioning

confidence: 99%

“…fabricated human serum albumin encapsulated bevacizumab nanoparticles containing 0.05 g tween 80 with PDI = 0.8. [41] .Tayyab et al fabricated and optimized the loading of febuxostat to chitosan nanocarriers and demonstrated a PDI lower than 0.5 for hydrophobic drug delivery systems [42] . Zhu et al prepared osteogenic peptidesloaded nanoliposomes with PDI value ranges 0.27 to 0.32.…”

Section: Characterizationmentioning

confidence: 99%

A Novel Carrier Based on DNA and Exosome to Sustained Release of 5‐Fluorouracil Anticancer Drug

Oraki,

Saeidifar,

Khanlarkhani

et al. 2024

ChemistrySelect

View full text Add to dashboard Cite

The development of effective drug delivery systems is crucial for improving cancer treatment outcomes. A promising carrier using a combination of DNA and exosomes (EXO) was synthesized to sustain the release of the powerful anticancer drug 5‐fluorouracil (5‐FU). The carrier was prepared by encapsulating 5‐FU‐loaded exosomes (5‐FU.EXO) in the heated DNA carriers (5‐FU.EXO@DNA). Alteration of the DNA structure was studied using molecular dynamics. The physicochemical properties of the carriers were characterized using fourier‐transform infrared spectroscopy (FTIR), field‐emission scanning electron microscopy (FESEM), and dynamic light scattering (DLS). The 5‐FU.EXO@DNA carrier exhibited good stability and biocompatibility, with a uniform size distribution (709±269 nm) and a zeta potential of +312 mV. The interaction between 5‐FU and DNA was confirmed using molecular docking. In vitro release studies showed that both 5‐FU@DNA and 5‐FU.EXO@DNA carriers achieved sustained release of 5‐FU for 576 h, with cumulative releases of approximately 83 % and 89 %, respectively. The 5‐FU release profile showed 40 % release over 86 h. The release rate and other kinetic parameters were also determined. Furthermore, the release kinetics followed by the Korsmeyer‐Peppas model and the diffusion mechanism plays a significant role in controlling the release process.

show abstract

“…In contrast, in nanocapsules, therapeutic agents are being held in an aqueous or oily cavity surrounded by a uni-polymeric membrane [ 94 ]. Further, the most commonly adopted biodegradable synthetic and natural polymers to develop this kind of NPs are poly(lactide-co-glycolide) (PLGA) [ 270 ], polylactide (PLA) [ 271 ] , polycaprolactone (PCL) [ 272 ], PLGA-polyethylene glycol (PEG) [ 273 ], alginate [ 274 ], gelatin [ 275 ], albumin [ 276 ], etc. Recently, an investigation by Wang and colleagues developed DOX-loaded cRGD-attached reduction-responsive crosslinked nanotherapeutics based on star PLGA-lipoic acid conjugate (cRGD-sPLGA XNPs) to achieve targeted delivery to melanoma (Fig.…”

Section: Polymer-based Nanoparticles For Skin Cancer Therapymentioning

confidence: 99%

Advancements in nanoparticle-based treatment approaches for skin cancer therapy

et al. 2023

View full text Add to dashboard Cite

Skin cancer has emerged as the fifth most commonly reported cancer in the world, causing a burden on global health and the economy. The enormously rising environmental changes, industrialization, and genetic modification have further exacerbated skin cancer statistics. Current treatment modalities such as surgery, radiotherapy, conventional chemotherapy, targeted therapy, and immunotherapy are facing several issues related to cost, toxicity, and bioavailability thereby leading to declined anti-skin cancer therapeutic efficacy and poor patient compliance. In the context of overcoming this limitation, several nanotechnological advancements have been witnessed so far. Among various nanomaterials, nanoparticles have endowed exorbitant advantages by acting as both therapeutic agents and drug carriers for the remarkable treatment of skin cancer. The small size and large surface area to volume ratio of nanoparticles escalate the skin tumor uptake through their leaky vasculature resulting in enhanced therapeutic efficacy. In this context, the present review provides up to date information about different types and pathology of skin cancer, followed by their current treatment modalities and associated drawbacks. Furthermore, it meticulously discusses the role of numerous inorganic, polymer, and lipid-based nanoparticles in skin cancer therapy with subsequent descriptions of their patents and clinical trials. Graphical Abstract

show abstract

Effect of nano-encapsulation using human serum albumin on anti-angiogenesis activity of bevacizumab to target corneal neovascularization: Development, optimization and in vitro assessment

Cited by 9 publications

References 29 publications

Biofunctionalization of 3D printed collagen with bevacizumab-loaded microparticles targeting pathological angiogenesis

Biofunctionalization of 3D printed collagen with bevacizumab-loaded microparticles targeting pathological angiogenesis

A Novel Carrier Based on DNA and Exosome to Sustained Release of 5‐Fluorouracil Anticancer Drug

Advancements in nanoparticle-based treatment approaches for skin cancer therapy

Contact Info

Product

Resources

About